Analysis BioNTech’s Pivotal Year: Clinical Data Holds Key to Oncology Ambitions
Having moved beyond its defining role in the COVID-19 pandemic, BioNTech now faces a critical juncture. The company’s future as a diversified oncology leader hinges on clinical proof, with a...